Intravenous tissue plasminogen activator (tPA) was US Food and Drug Administration (FDA) approved for the treatment of acute ischemic stroke in 1996 after the National Institute of Neurological Disorders and Stroke trial and has been the main stay of treatment ever since. Here, PLAT is linked to Stroke.